| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Biomea Fusion (NASDAQ:BMEA) through any online brokerage.
Other companies in Biomea Fusion’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Biomea Fusion has a consensus price target of $16.88.
The stock price for Biomea Fusion (NASDAQ: BMEA) is $0.765 last updated October 20, 2026 at 7:36 PM EDT.
There are no upcoming dividends for Biomea Fusion.
Biomea Fusion does not have any upcoming earnings scheduled.
There is no upcoming split for Biomea Fusion.
Biomea Fusion is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
